

**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Currently amended). An injectable [[A]] chemotherapeutic pharmaceutical composition medicament consisting of a sodium or potassium salt of a halogenated xanthene in aqueous solution as the active component, wherein said pharmaceutical composition chemotherapeutic medicament is for chemotherapeutic treatment of diseases of human and animal tissue.

Claim 2 (Currently amended). The pharmaceutical composition medicament of Claim 1 wherein said halogenated xanthene is present in a concentration of greater than about 0.001% to less than about 20%.

Claim 3 (Currently amended). The pharmaceutical composition medicament of Claim 1 wherein said halogenated xanthene is Rose Bengal.

Claim 4 (Currently amended). The pharmaceutical composition medicament of Claim 1 wherein said halogenated xanthene is a compound selected from the group consisting of 4',5'-Dichlorofluorescein; 2',7'-Dichlorofluorescein; 4,5,6,7-Tetrachlorofluorescein; 2',4',5',7'-Tetrachlorofluorescein; Dibromofluorescein; Solvent Red 72; Diiodofluorescein; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein.

Claims 5-8 (Canceled).

Claim 9 (Currently amended). The pharmaceutical composition medicament of Claim 1 wherein said solution halogenated xanthene is in a delivery vehicle that includes an adjuvant selected from the group consisting of builders, stabilizers, emulsifiers, dispersants, preservatives, buffers and [[,]] electrolytes ,tissue penetrating agents and tissue softening agents.

Claim 10 (Currently amended). The pharmaceutical composition medicament of Claim 1 wherein said pharmaceutical composition medicament is for the treatment of indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the respiratory tract and related organs, diseases of the circulatory system and related organs, diseases of the head and neck, diseases of the endocrine and lymphoreticular systems and related organs, diseases of connective tissues, diseases of tissue surfaces exposed during surgery, and diseases caused by microbial, viral, fungal, and parasitic infection.

Claim 11 (Currently amended). The pharmaceutical composition medicament of Claim 1 wherein said medicament is administered using an intracorporeal [[a]] route of administration selected from the group consisting of intravenous injection, intraperitoneal injection, intramuscular injection, intracranial injection, intratumoral injection, intraepithelial injection, transcutaneous delivery, per oesophageal administration, intraabdominal administration, intraappendicular administration, intraarterial administration, intraarticular administration, intrabronchial administration, intrabuccal administration, intracapsular administration, intracardial administration, intracartilaginous administration, intracavitory administration, intracephalic administration, intracolic administration, intracutaneous administration, intracystic administration, intradermal administration, intraductal administration, intraduodenal administration, intrafascicular administration, intrafat administration, intrafilar administration, intrafissural administration, intragastric administration, intraglandular administration, intrahepatic administration, intraintestinal administration, intralamellar administration, intralesional administration, intraligamentous administration, intralingual administration, intramammary administration, intramedullary administration, intrameningeal administration, intramyocardial administration, intranasal administration, intraocular administration,

intraoperative administration, intraoral administration, intraosseous administration, intraovarian administration, intrapancreatic administration, intraparietal administration, intrapelvic administration, intrapericardial administration, intraperineal administration, intraperitoneal administration, intraplacental administration, intrapleural administration, intrapontine administration, intraprostatic administration, intrapulmonary administration, intrarachidian administration, intrarectal administration, intrarenal administration, intrascleral administration, intrascrotal administration, intrasegmental administration, intrasellar administration, intraspinal administration, intrasplenic administration, intrasternal administration, intrastromal administration, intrasynovial administration, intratarsal administration, intratesticular administration, intrathoracic administration, intratonsillar administration, intratracheal administration, intratubal administration, intratympanic administration, intraureteral administration, intraurethral administration, intrauterine administration, intravaginal administration, intravascular administration, intraventricular administration, intravertebral administration, intravesical administration, and intravitreous administration.

Claims 12-18 (Canceled).

Claim 19 (Currently amended). A chemotherapeutic pharmaceutical composition for intracorporeal administration consisting of a sodium or potassium salt of a halogenated xanthene formulated in a delivery vehicle consisting of an aqueous solution, a tablet, a capsule, a suppository or a syrup as the active component.

Claim 20 (Original). The pharmaceutical composition of Claim 19 wherein said halogenated xanthene is present in a concentration of greater than about 0.001% to less than about 20%.

Claim 21 (Previously presented). The pharmaceutical composition of Claim 19 wherein said halogenated xanthene is Rose Bengal.

Claim 22 (Previously presented). The pharmaceutical composition of Claim 19 wherein said halogenated xanthene is a compound selected from the group consisting of 4',5'-Dichlorofluorescein; 2',7'-Dichlorofluorescein; 4,5,6,7-Tetrachlorofluorescein; 2',4',5',7'-Tetrachlorofluorescein; Dibromofluorescein; Solvent Red 72; Diiodofluorescein; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein.

Claims 23-26 (Canceled).

Claim 27 (Currently amended). The pharmaceutical composition of Claim 19 wherein said halogenated xanthene is in a delivery vehicle that includes an adjuvant selected from the group consisting of builders, stabilizers, emulsifiers, dispersants, preservatives, buffers and [[,]] electrolytes, tissue penetrating agents and tissue softening agents.

Claims 28-33 (Canceled).